GlassScriptPhysician profile
Paresh A Rawal
NPI 1710985916
$5,402.82
in general payments reported to CMS, 2019-2025
19 companies · $313 in 2025
The $313 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $24.38 · 2021: $212 · 2022: $638 · 2023: $1,678 · 2024: $2,347 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,317 · Food and Beverage: $2,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,316.82 |
| Food and Beverage | $2,020.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,227.67 | 2022-2025 | Xact, Optis, Diamondback Coronary |
| Penumbra, INC. | $1,158.90 | 2023 | Indigo System |
| Novartis Pharmaceuticals Corporation | $416.64 | 2019-2025 | |
| Boston Scientific Corporation | $397.31 | 2022-2024 | Ekosonic, Watchman Flx, Peripheral Rotalink Plus |
| Abiomed | $213.45 | 2021-2025 | |
| Medtronic, INC. | $191.55 | 2022-2025 | Hawkone, Turbohawk |
| Merck Sharp & Dohme LLC | $151.44 | 2019-2025 | Verquvo, Winrevair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.60 | 2022-2023 | Jardiance |
| Amgen INC. | $106.88 | 2022-2025 | Repatha |
| Novo Nordisk INC | $85.60 | 2024-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $84.81 | 2021-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $47.07 | 2021-2022 | |
| Ge Healthcare | $42.90 | 2021 | |
| Amarin Pharma, INC. | $32.80 | 2022 | |
| Pfizer INC. | $27.02 | 2023-2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.38 | 2020 | |
| Angiodynamics, INC. | $20.19 | 2023 | Venacure 1470 Pro |
| Lexicon Pharmaceuticals, INC. | $15.47 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.14 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paresh Rawal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.